AEterna Zentaris Inc. (AEZS)

[alexander77]

Why $10 million more for only 3 millionshares
Brings to a total of 12,9 million outstanding shares. According to the AF biotech oncology rule that would gives AEZS a pre FDA-approval market cap of at least $300m between now and the next 12 months or at least $24/share.
Now why the need for $10m extra in cash?
1. To license additional products they can sell to increase their revenue base (listen or read the CC)
2. To prepare commercialization of Zoptrex, marketing efforts (listen or read to the CC)
3. To increase their sales force
4. To increase their negotiation position for more partnerships
5. To defend themselves against a hostile takeover